Published in Nat Genet on October 15, 2002
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Biomarkers for epithelial-mesenchymal transitions. J Clin Invest (2009) 8.76
The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A (2005) 7.38
The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol (2012) 7.32
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell (2007) 3.82
Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol (2010) 3.77
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer (2014) 3.37
No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet (2008) 3.32
Breast cancer: origins and evolution. J Clin Invest (2007) 3.31
Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol (2005) 3.19
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood (2009) 3.02
The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle (2010) 2.69
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget (2010) 2.44
Non-cell-autonomous tumor suppression by p53. Cell (2013) 2.40
Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res (2003) 2.37
Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Mol Cell Biol (2006) 2.34
Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res (2011) 2.26
Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol (2009) 2.25
Microenvironmental regulation of cancer development. Curr Opin Genet Dev (2008) 2.25
Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol (2009) 2.20
Fibroblast heterogeneity in the cancer wound. J Exp Med (2014) 2.09
SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet (2008) 2.00
Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 1.87
The search for genes contributing to endometriosis risk. Hum Reprod Update (2008) 1.58
Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia (2011) 1.56
The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol (2005) 1.56
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res (2008) 1.52
PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res (2004) 1.49
Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. Oncogene (2010) 1.47
Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet (2003) 1.41
The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol (2009) 1.40
Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer (2008) 1.39
Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am J Hum Genet (2006) 1.31
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing. Oncologist (2014) 1.24
Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions. Clin Exp Metastasis (2007) 1.23
Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc Natl Acad Sci U S A (2008) 1.18
Cancer evolution and individual susceptibility. Integr Biol (Camb) (2011) 1.15
Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res (2008) 1.15
The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. Genes Cancer (2011) 1.14
Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis (2008) 1.13
Pancreatic cancer associated fibroblasts display normal allelotypes. Cancer Biol Ther (2008) 1.13
p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res (2010) 1.12
The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell Int (2014) 1.11
Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer (2005) 1.11
Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. J Clin Invest (2014) 1.10
Cancer cells suppress p53 in adjacent fibroblasts. Oncogene (2008) 1.10
Stromal deletion of the APC tumor suppressor in mice triggers development of endometrial cancer. Cancer Res (2011) 1.10
A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer (2006) 1.10
MicroRNA regulons in tumor microenvironment. Oncogene (2014) 1.08
Tumor stroma as targets for cancer therapy. Pharmacol Ther (2012) 1.06
RIN1 is a breast tumor suppressor gene. Cancer Res (2007) 1.05
Mutations in bone marrow-derived stromal stem cells unmask latent malignancy. Stem Cells Dev (2010) 1.05
Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br J Cancer (2008) 1.04
Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies. Breast Cancer Res (2008) 1.04
Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy. Clin Cancer Res (2013) 1.04
Stromal fibroblasts in digestive cancer. Cancer Microenviron (2010) 1.03
Pten in the breast tumor microenvironment: modeling tumor-stroma coevolution. Cancer Res (2011) 1.02
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.01
Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Res (2007) 1.01
Cancer-stromal cell interaction and tumor angiogenesis in gastric cancer. Cancer Microenviron (2009) 1.00
Perspectives on tissue interactions in development and disease. Curr Mol Med (2010) 1.00
Wnt1 expression induces short-range and long-range cell recruitments that modify mammary tumor development and are not induced by a cell-autonomous beta-catenin effector. Cancer Res (2008) 1.00
Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer Microenviron (2009) 0.99
Identification of alterations in DNA copy number in host stromal cells during tumor progression. Proc Natl Acad Sci U S A (2006) 0.99
The role of fibroblast Tiam1 in tumor cell invasion and metastasis. Oncogene (2010) 0.98
Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel. Int J Cancer (2013) 0.98
Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer (2008) 0.98
The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis (2007) 0.95
Stromal cells and integrins: conforming to the needs of the tumor microenvironment. Neoplasia (2009) 0.95
Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression. Clin Exp Metastasis (2011) 0.95
Mesenchymal stroma: primary determinant and therapeutic target for epithelial cancer. Trends Cell Biol (2013) 0.94
Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. BMC Cancer (2011) 0.94
Using real-time impedance-based assays to monitor the effects of fibroblast-derived media on the adhesion, proliferation, migration and invasion of colon cancer cells. Biosci Rep (2014) 0.93
CD248 facilitates tumor growth via its cytoplasmic domain. BMC Cancer (2011) 0.93
Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development. Hum Mol Genet (2007) 0.92
High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer. Breast Cancer Res (2006) 0.91
PTEN and p53 cross-regulation induced by soy isoflavone genistein promotes mammary epithelial cell cycle arrest and lobuloalveolar differentiation. Carcinogenesis (2010) 0.91
Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients. Biomed Res Int (2014) 0.91
Mitochondrial Oxidative Stress due to Complex I Dysfunction Promotes Fibroblast Activation and Melanoma Cell Invasiveness. J Signal Transduct (2012) 0.90
Breast cancer, stem cells and prospects for therapy. Breast Cancer Res (2006) 0.90
The Role of miRNAs as Key Regulators in the Neoplastic Microenvironment. Mol Biol Int (2011) 0.90
MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One (2013) 0.90
Roles of tumor suppressors in regulating tumor-associated inflammation. Cell Death Differ (2014) 0.89
Hematopoietic stem cell derived carcinoma-associated fibroblasts: a novel origin. Int J Clin Exp Pathol (2012) 0.89
Human breast fibroblasts inhibit growth of the MCF10AT xenograft model of proliferative breast disease. Am J Pathol (2007) 0.88
Evaluation of ultra-deep targeted sequencing for personalized breast cancer care. Breast Cancer Res (2013) 0.88
Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade. Br J Cancer (2004) 0.88
Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy (2012) 0.88
Involvement of stromal p53 in tumor-stroma interactions. Semin Cell Dev Biol (2009) 0.87
Seed in soil, with an epigenetic view. Biochim Biophys Acta (2008) 0.86
Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers (Basel) (2012) 0.85
A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy. Neoplasia (2013) 0.85
In vitro models of pancreatic cancer for translational oncology research. Expert Opin Drug Discov (2009) 0.84
MicroRNA regulation in cancer-associated fibroblasts. Cancer Immunol Immunother (2011) 0.84
The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. Stem Cell Rev (2015) 0.84
Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif. Hum Mutat (2009) 0.83
Pan-cancer analysis of TCGA data reveals notable signaling pathways. BMC Cancer (2015) 0.83
Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients. Cancer Biol Ther (2013) 0.83
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med (2002) 6.94
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (2007) 6.47
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA (2004) 4.52
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res (2008) 3.41
Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res (2012) 3.33
Validation of proposed DSM-5 criteria for autism spectrum disorder. J Am Acad Child Adolesc Psychiatry (2011) 2.72
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet (2007) 2.64
Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA (2005) 2.59
A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet (2010) 2.59
PTEN hamartoma tumor syndrome: an overview. Genet Med (2009) 2.44
Protean PTEN: form and function. Am J Hum Genet (2002) 2.43
Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet (2003) 2.43
Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res (2003) 2.37
Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA (2010) 2.36
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
The nuclear affairs of PTEN. J Cell Sci (2008) 2.34
From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nat Rev Genet (2003) 2.26
Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery (2008) 2.26
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res (2011) 2.25
PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol (2002) 2.16
Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol (2007) 2.16
Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer (2006) 2.13
Prolapse-related changes are a confounding factor in misdiagnosis of sessile serrated adenomas in the rectum. Hum Pathol (2012) 2.10
A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab (2006) 2.10
Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer (2002) 2.02
SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet (2008) 2.00
A time study of cancer genetic counselors using a genetic counselor-only patient care model versus a traditional combined genetic counselor plus medical geneticist care model. J Natl Compr Canc Netw (2013) 2.00
Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet (2008) 1.96
Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology (2010) 1.96
Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet (2003) 1.94
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Highly penetrant hereditary cancer syndromes. Oncogene (2004) 1.84
Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet (2012) 1.84
Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res (2005) 1.84
Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.78
Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res (2004) 1.76
The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer. J Pathol (2012) 1.72
Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res (2002) 1.71
Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res (2003) 1.67
Frequency of germline genomic homozygosity associated with cancer cases. JAMA (2008) 1.67
Unusual features in a patient with neurofibromatosis type 1: multiple subcutaneous lipomas, a juvenile polyp in ascending colon, congenital intrahepatic portosystemic venous shunt, and horseshoe kidney. Am J Med Genet A (2004) 1.67
CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res (2012) 1.64
Prospective comparison of family medical history with personal genome screening for risk assessment of common cancers. Eur J Hum Genet (2012) 1.62
Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA (2007) 1.60
Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet (2008) 1.59
Multiple endocrine neoplasia type 2: an overview. Genet Med (2011) 1.58
Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab (2007) 1.57
Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol (2008) 1.56
BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet (2003) 1.54
Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer (2006) 1.53
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53
Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. Digestion (2011) 1.51
Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology (2013) 1.49
PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene (2004) 1.49
Increasing structure dimensionality of copper(I) complexes by varying the flexible thioether ligand geometry and counteranions. Inorg Chem (2006) 1.49
Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene (2003) 1.47
Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet (2003) 1.41
Cowden syndrome. Semin Oncol (2007) 1.39
Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet (2007) 1.39
Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res (2009) 1.38
S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol (2004) 1.37
Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol (2004) 1.37
The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet (2002) 1.36
Defining phenotypes and cancer risk in hyperplastic polyposis syndrome. Dis Colon Rectum (2011) 1.36
Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res (2007) 1.34
Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev (2006) 1.33
Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer (2011) 1.33
Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol (2013) 1.33
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res (2005) 1.33
Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am J Hum Genet (2006) 1.31
The approach to the patient with paraganglioma. J Clin Endocrinol Metab (2009) 1.30
Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med (2009) 1.30
A comparison of the neurotoxic effects on the spinal cord of tetracaine, lidocaine, bupivacaine, and ropivacaine administered intrathecally in rabbits. Anesth Analg (2003) 1.28
Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat (2009) 1.26
Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer (2006) 1.26
Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur J Hum Genet (2011) 1.25
Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab (2011) 1.25
Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med (2007) 1.24
Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes. Am J Hum Genet (2006) 1.24
Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Res (2003) 1.24
Microenvironmental genomic alterations and clinicopathological behavior in head and neck squamous cell carcinoma. JAMA (2007) 1.24
Renal cancer in von Hippel-Lindau disease and related syndromes. Nat Rev Nephrol (2013) 1.23
Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer. Clin Cancer Res (2003) 1.23
Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat Clin Pract Endocrinol Metab (2008) 1.22
Psoriasin interacts with Jab1 and influences breast cancer progression. Cancer Res (2003) 1.20
Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab (2005) 1.20
Unregulated smooth-muscle myosin in human intestinal neoplasia. Proc Natl Acad Sci U S A (2008) 1.20
Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Hum Mol Genet (2011) 1.19
PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner. Cancer Res (2006) 1.19